Recent Publications by UCB Pharma: |
A pharmacodynamic Markov mixed-effects model for determining the effect of exposure to certolizumab pegol on the ACR20 score in patients with rheumatoid arthritis.
The American College of Rheumatology (ACR) 20% preliminary definition of... | 10th October, 2009
| Pharmacometrics, Department of Global Exploratory Development, UCB Pharma
| Clin Pharmacol Ther. 2009 Oct;86(4):387-95. Epub 2009 Jul 22.
DOI Direct Link |
The inhibitory avoidance test optimized for discovery of cognitive enhancers.
In the present article, we describe a new protocol for the inhibitory... | 2nd October, 2009
| CNS Pharmacology Department-Cognitive Psychopharmacology, UCB Pharma,
| Behav Res Methods. 2009 Aug;41(3):805-11.
DOI Direct Link |
A risk-based analysis of the AAPS conference report on quantitative bioanalytical methods validation and implementation.
The 3rd American Association of Pharmaceutical Scientists (AAPS)/Food and... | 25th September, 2009
| UCB Pharma, Exploratory Statistics, Braine L'Alleud, Belgium.
| J Chromatogr B Analyt Technol Biomed Life Sci. 2009 Aug 1;877(23):2235-43.
DOI Direct Link |
Brivaracetam inhibits spreading depression in rat neocortical slices in vitro.
Epilepsy and migraine are episodic neurological disorders with marked... | 11th September, 2009
| UCB Pharma SA, CNS Research, Braine-l'Alleud, Belgium.
| Seizure. 2009 Jul;18(6):453-6. Epub 2009 Feb 10.
DOI Direct Link |
Profile of the new pyrrolidone derivative seletracetam (ucb 44212) in animal models of epilepsy.
Seletracetam is a pyrrolidone derivative with a one-log-unit higher... | 26th August, 2009
| CNS Research, UCB Pharma SA, Chemin du Foriest, B-1420 Braine-l'Alleud,
| Eur J Pharmacol. 2009 Jul 1;614(1-3):30-7. Epub 2009 Apr 19.
DOI Direct Link |
Levetiracetam extended release and levetiracetam immediate release as adjunctive treatment for partial-onset seizures: an indirect comparison of treatment-emergent adverse events using meta-analytic techniques.
The safety profiles of once-daily adjunctive levetiracetam (LEV) extended... | 25th August, 2009
| G3P Epidemiology, UCB Pharma S.A., Brussels, Belgium.
| Epilepsy Behav. 2009 Oct;16(2):240-5. Epub 2009 Aug 20.
DOI Direct Link |
Pharmacokinetics of levetiracetam XR 500mg tablets.
PURPOSE: To compare the relative bioavailability of levetiracetam... | 25th July, 2009
| UCB Pharma S.A., Braine-l'Alleud, Belgium.
| Epilepsy Res. 2009 Apr;84(2-3):224-31. Epub 2009 Mar 4.
DOI Direct Link |
Repeated assessment of cardiovascular and respiratory functions using combined telemetry and whole-body plethysmography in the rat.
INTRODUCTION: As the currently recommended laboratory techniques for... | 21st July, 2009
| Department of Non Clinical Development, Non Clinical Safety Pharmacology
| J Pharmacol Toxicol Methods. 2009 Sep-Oct;60(2):117-29. Epub 2009 Jul 17.
DOI Direct Link |
Gender and interindividual variability in pharmacokinetics.
Like any other drugs, antiallergic medications can be associated with... | 16th July, 2009
| UCB Pharma SA, Chemin du Foriest, Braine I' Alleud, B-1420 Belgium.
| Drug Metab Rev. 2009;41(3):408-21.
DOI Direct Link |
Physiologically based pharmacokinetics (PBPK).
Allometric scaling is widely used to predict human pharmacokinetic... | 16th July, 2009
| UCB Pharma SA, Belgium.
| Drug Metab Rev. 2009;41(3):391-407.
DOI Direct Link |
Drug metabolism and pharmacokinetics.
In this article, aspects of absorption, distribution, metabolism, and... | 16th July, 2009
| UCB
| Drug Metab Rev. 2009;41(3):344-90.
DOI Direct Link |
Proepileptic phenotype of SV2A-deficient mice is associated with reduced anticonvulsant efficacy of levetiracetam.
Summary Purpose: Synaptic vesicle protein 2A (SV2A) constitutes a distinct... | 3rd June, 2009
| UCB Pharma S.A., CNS Research, B-1420 Braine-l'Alleud, Belgium.
| Epilepsia. 2009 Apr 19.
DOI Direct Link |
Behavioural phenotyping reveals anxiety-like features of SV2A deficient mice.
Synaptic vesicle protein 2A (SV2A) is involved in neurotransmitter release... | 23rd April, 2009
| Preclinical CNS Research, UCB Pharma s.a., Braine-l'Alleud, Belgium.
| Behav Brain Res. 2009 Mar 17;198(2):329-33. Epub 2008 Nov 11.
DOI Direct Link |
Selection of cytotoxicity markers for the screening of new chemical entities in a pharmaceutical context: a preliminary study using a multiplexing approach.
The present study was undertaken to validate a battery of cytotoxicity... | 15th April, 2009
| UCB Pharma SA, Investigative Non-Clinical Safety, Non-Clinical
| Toxicol In Vitro. 2009 Mar;23(2):319-32. Epub 2008 Dec 10.
DOI Direct Link |
GPCRs in medicinal chemistry.
The present study was undertaken to validate a battery of cytotoxicity... | 31st January, 2009
| UCB Pharma SA,B-1420, Braine-l'Alleud, Belgium.
| IDrugs. 2008 Dec;11(12):870-5.
|
